<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7038234/results/search/drug/results.xml">
  <result pre="extracts library was performed, and two hit FDA-approved Na+/K+-ATPase inhibitors," exact="ouabain" post="and digoxin, were identified as having robust efficiency against"/>
  <result pre="with the selectivity indexes over 1,000. The results indicated that" exact="ouabain" post="and digoxin blocked the JEV infection at the replication"/>
  <result pre="selectivity indexes over 1,000. The results indicated that ouabain and" exact="digoxin" post="blocked the JEV infection at the replication stage by"/>
  <result pre="stage by targeting the Na+/K+-ATPase. Furthermore, it was proven that" exact="ouabain" post="significantly reduced the morbidity and mortality caused by JEV"/>
  <result pre="serve as the target of treatment of JEV infection, and" exact="ouabain" post="has the potential to be developed as an effective"/>
  <result pre="anti-JEV drug. KEYWORDS high-content screening (HCS) Japanese encephalitis virus (JEV)" exact="ouabain" post="digoxin Na+/K+-ATPase Funding National Key Research and Development Program"/>
  <result pre="drug. KEYWORDS high-content screening (HCS) Japanese encephalitis virus (JEV) ouabain" exact="digoxin" post="Na+/K+-ATPase Funding National Key Research and Development Program of"/>
  <result pre="(7), dehydroepiandrosterone (8), N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) (9), indirubin (10)," exact="manidipine" post="(11), chlorpromazine (12), etanercept (13), and minocycline (14), few"/>
  <result pre="(8), N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) (9), indirubin (10), manidipine (11)," exact="chlorpromazine" post="(12), etanercept (13), and minocycline (14), few therapies beyond"/>
  <result pre="for discovering inhibitors against JEV infection. Two hit FDA-approved compounds," exact="ouabain" post="and digoxin, were identified to inhibit JEV infection both"/>
  <result pre="selected for the second screening because of their solubility in" exact="dimethyl sulfoxide" post="(DMSO) at room temperature and absence of any obvious"/>
  <result pre="viability of &amp;gt;80% (Fig. 2A and B). Among the 8 compounds," exact="ouabain" post="and digoxin were subjected to further investigation because of"/>
  <result pre="(Fig. 2A and B). Among the 8 compounds, ouabain and" exact="digoxin" post="were subjected to further investigation because of their high"/>
  <result pre="(SDs) from at least two independent experiments. Antiviral effects of" exact="ouabain" post="and digoxin in different cell lines and viruses. For"/>
  <result pre="at least two independent experiments. Antiviral effects of ouabain and" exact="digoxin" post="in different cell lines and viruses. For AT31 infection"/>
  <result pre="cell lines and viruses. For AT31 infection of Vero cells," exact="digoxin" post="(392 nM) and ouabain (196 nM) displayed inhibition rates &amp;gt;90%; the"/>
  <result pre="viruses. For AT31 infection of Vero cells, digoxin (392 nM) and" exact="ouabain" post="(196 nM) displayed inhibition rates &amp;gt;90%; the ability to block"/>
  <result pre="SA14 reproduction could be greatly inhibited when the concentration of" exact="digoxin" post="and ouabain reached 392 nM and 98 nM, respectively, Simultaneously, the"/>
  <result pre="could be greatly inhibited when the concentration of digoxin and" exact="ouabain" post="reached 392 nM and 98 nM, respectively, Simultaneously, the fluorescence signal"/>
  <result pre="(Fig. 3B). FIG 3 Validation of the antiviral effects of" exact="ouabain" post="and digoxin in different cell lines and virus strains."/>
  <result pre="FIG 3 Validation of the antiviral effects of ouabain and" exact="digoxin" post="in different cell lines and virus strains. The antiviral"/>
  <result pre="different cell lines and virus strains. The antiviral effects of" exact="digoxin" post="and ouabain against two JEV strains (AT31 and SA14)"/>
  <result pre="lines and virus strains. The antiviral effects of digoxin and" exact="ouabain" post="against two JEV strains (AT31 and SA14) in Vero"/>
  <result pre="assessed by qRT-PCR. (G to J) The antiviral effects of" exact="digoxin" post="and ouabain against two JEV strains in Huh-7 cells"/>
  <result pre="qRT-PCR. (G to J) The antiviral effects of digoxin and" exact="ouabain" post="against two JEV strains in Huh-7 cells and U251"/>
  <result pre="**, P &amp;lt; 0.01; *, P &amp;lt; 0.05. Under the same conditions of infection," exact="ouabain" post="and digoxin robustly inhibited AT31 and SA14 virus production"/>
  <result pre="*, P &amp;lt; 0.05. Under the same conditions of infection, ouabain and" exact="digoxin" post="robustly inhibited AT31 and SA14 virus production in a"/>
  <result pre="the two cell lines (Fig. 3G to J). Ouabain and" exact="digoxin" post="inhibit JEV infection during viral RNA synthesis. To determine"/>
  <result pre="was performed (Fig. 4A). As shown in Fig. 4B, neither" exact="digoxin" post="nor ouabain showed suppression of JEV in virucidal treatments"/>
  <result pre="(Fig. 4A). As shown in Fig. 4B, neither digoxin nor" exact="ouabain" post="showed suppression of JEV in virucidal treatments or pretreatments."/>
  <result pre="showed suppression of JEV in virucidal treatments or pretreatments. However," exact="ouabain" post="showed a robust inhibition of JEV during treatment. Most"/>
  <result pre="of JEV during treatment. Most importantly, when added posttreatment, both" exact="ouabain" post="and digoxin exerted full inhibitory effects on JEV infection,"/>
  <result pre="during treatment. Most importantly, when added posttreatment, both ouabain and" exact="digoxin" post="exerted full inhibitory effects on JEV infection, suggesting that"/>
  <result pre="and JEV reporter replicon assay of the antiviral activities of" exact="ouabain" post="and digoxin. (A) Schematic illustration of the time-of-addition experiment."/>
  <result pre="illustration of the time-of-addition experiment. (B) The inhibitory effects of" exact="digoxin" post="and ouabain with the indicated concentration in each group,"/>
  <result pre="the time-of-addition experiment. (B) The inhibitory effects of digoxin and" exact="ouabain" post="with the indicated concentration in each group, determined by"/>
  <result pre="Huh-7 cells transfected with the JEV replicon were treated with" exact="digoxin" post="and ouabain, respectively, and luciferase activities were determined as"/>
  <result pre="the JEV replicon were treated with the indicated concentration of" exact="ouabain" post="and digoxin; we revealed the appreciable reduction of luciferase"/>
  <result pre="inhibit JEV infection at the replication stage. JEV inhibition with" exact="ouabain" post="and digoxin occurs via Na+/K+-ATPase. Na+/K+-ATPase is the only"/>
  <result pre="infection at the replication stage. JEV inhibition with ouabain and" exact="digoxin" post="occurs via Na+/K+-ATPase. Na+/K+-ATPase is the only target of"/>
  <result pre="(Fig. 5B). Under the same experimental conditions, the results of" exact="ouabain" post="action were consistent with digoxin (Fig. 5C and D),"/>
  <result pre="experimental conditions, the results of ouabain action were consistent with" exact="digoxin" post="(Fig. 5C and D), which indicated that the JEV-inhibiting"/>
  <result pre="but inversely correlated with KCl. These results confirm that both" exact="ouabain" post="and digoxin exert the antiviral effect by targeting the"/>
  <result pre="correlated with KCl. These results confirm that both ouabain and" exact="digoxin" post="exert the antiviral effect by targeting the Na+/K+-ATPase. FIG"/>
  <result pre="by targeting the Na+/K+-ATPase. FIG 5 Inhibition of JEV with" exact="digoxin" post="and ouabain occurs via Na+/K+-ATPase. Vero cells infected with"/>
  <result pre="the Na+/K+-ATPase. FIG 5 Inhibition of JEV with digoxin and" exact="ouabain" post="occurs via Na+/K+-ATPase. Vero cells infected with JEV AT31"/>
  <result pre="P &amp;lt; 0.05. Ouabain protects against JEV infection-induced lethality in vivo. As" exact="ouabain" post="exhibited a stronger inhibitory activity on JEV infections, we"/>
  <result pre="on JEV infections, we further examined the protective effect of" exact="ouabain" post="on JEV-induced lethality by using the BALB/c mouse. As"/>
  <result pre="out of 14 animals survived) (Fig. 6A). Mice treated with" exact="ouabain" post="alone showed little abnormal behavior. These results suggest that"/>
  <result pre="ouabain alone showed little abnormal behavior. These results suggest that" exact="ouabain" post="provides effective protection against JEV-induced mortality. FIG 6 Ouabain"/>
  <result pre="BALB/c mice were infected with 1 × 106 PFU of JEV together with" exact="ouabain" post="or vehicle by intraperitoneal route. (A) Survival of mice"/>
  <result pre="The results indicated that, during the progression of the disease," exact="ouabain" post="treatment significantly reduced viral load in infected mice compared"/>
  <result pre="the JEV-infected and vehicle-treated group on day 7 postinfection, while" exact="ouabain" post="treatment remarkably alleviated these phenomena (Fig. 6C). These results"/>
  <result pre="reduction in mortality rate, further confirming the curative effects of" exact="ouabain" post="on viral encephalitis. The viral loads of brain, blood,"/>
  <result pre="postinfection, viral titers in the brain were almost undetectable, and" exact="ouabain" post="exhibited little effect on viral titers in the brain"/>
  <result pre="viral titers in the brain at the preclinical stage. Accordingly," exact="ouabain" post="had little effect on decreasing viral titers in the"/>
  <result pre="the characteristic viremia caused by JEV. These results indicate that" exact="ouabain" post="could alleviate histopathological changes and reduce viral loads in"/>
  <result pre="mice against JEV-induced lethality and confirming the curative effects of" exact="ouabain" post="on viral encephalitis. DISCUSSION JEV continues to spread in"/>
  <result pre="effective and credible. The top two compounds, FDA-approved Na+/K+-ATPase inhibitors" exact="ouabain" post="and digoxin, are cardiac glycosides with similar chemical structures"/>
  <result pre="of cardiac arrhythmias and hypotension for more than 200 years. Recently," exact="ouabain" post="and digoxin have been proven to inhibit different kinds"/>
  <result pre="arrhythmias and hypotension for more than 200 years. Recently, ouabain and" exact="digoxin" post="have been proven to inhibit different kinds of viruses,"/>
  <result pre="variants by serial passaging of JEV using increasing concentrations of" exact="digoxin" post="and ouabain, respectively. However, no adaptive mutant was found"/>
  <result pre="biosynthetic signaling and vesicular sorting pathways (26). In this study," exact="ouabain" post="exhibited therapeutic effects on JEV infection in an adult"/>
  <result pre="two mechanisms that may contribute to the antiviral effects. First," exact="ouabain" post="may block JEV infection by inducing the cellular stress"/>
  <result pre="of BBB caused by JEV infection may have allowed BBB-nonpermissive" exact="ouabain" post="to enter the brain, bind the murine ATPase α2"/>
  <result pre="be used in future clinical trials examining the effects of" exact="ouabain" post="on JEV infection. Moreover, our results indicate that ATPase"/>
  <result pre="z values under different conditions as previously described (11); 10 μM" exact="manidipine" post="and 0.5% DMSO were used as positive and negative"/>
  <result pre="calculated using the associated Harmony 3.5 software. Antiviral effects of" exact="ouabain" post="and digoxin with different cell lines and virus strains."/>
  <result pre="the associated Harmony 3.5 software. Antiviral effects of ouabain and" exact="digoxin" post="with different cell lines and virus strains. Vero, Huh-7,"/>
  <result pre="for 1 h (0 to 1 h). Ouabain (10 μM) and" exact="digoxin" post="(10 μM) were incubated with the cells for 1 h"/>
  <result pre="cells for at least triplicate repeat experiments. Antiviral efficacy of" exact="ouabain" post="in BALB/c mice. Adult male BALB/c mice (4 weeks) were"/>
  <result pre="PFU JEV (AT31). The infected mice were i.p. administered with" exact="ouabain" post="at 3 mg/kg of body weight or a vehicle control"/>
 </snippets>
</snippetsTree>
